Abstract
Diabetes mellitus, a chronic condition caused by defects in insulin secretion, or action, or both, is a group of metabolic disorders whose complications can contribute significantly to ill health, disability, poor quality of life and premature death. From the three main types of diabetes, Type 2 is by far the most common, accounting for about 90% of cases worldwide. Studies on the role of protein tyrosine phosphatase 1B (PTP1B) have clearly shown that it serves as a key negative regulator of insulin signaling and is involved in the insulin resistance associated with Type 2 diabetes. In the present study, a QSAR modeling work was carried out on a series of 1, 2-naphthoquinone derivatives. The inhibitory activity of such compounds was investigated by two types of QSAR methods: multiple linear regression and non-linear neural networks. This strategy afforded QSAR models with good overall accuracy and predictivity on external data, showing it to be a simple, precise and credible tool to predict and screen 1,2-naphoquinone derivatives with high inhibitory activity.
Keywords: Diabetes mellitus, Multiple linear regression (MLR), 1, 2-naphoquinone derivatives, Protein tyrosine phosphatase 1B (PTP1B), Quantitative structure-activity relationships (QSAR), Radial basis function neural networks (RBFNN), hyperglycemia, toxicology, benzothiophene, peptidomimetic derivatives
Letters in Drug Design & Discovery
Title:QSAR Studies of PTP1B Inhibitors: 1, 2-Naphthoquinone Derivatives
Volume: 9 Issue: 10
Author(s): Feng Luan, Xuan Xu, Huitao Liu, Maria Natalia Dias Soeiro Cordeiro and Xiaoyun Zhang
Affiliation:
Keywords: Diabetes mellitus, Multiple linear regression (MLR), 1, 2-naphoquinone derivatives, Protein tyrosine phosphatase 1B (PTP1B), Quantitative structure-activity relationships (QSAR), Radial basis function neural networks (RBFNN), hyperglycemia, toxicology, benzothiophene, peptidomimetic derivatives
Abstract: Diabetes mellitus, a chronic condition caused by defects in insulin secretion, or action, or both, is a group of metabolic disorders whose complications can contribute significantly to ill health, disability, poor quality of life and premature death. From the three main types of diabetes, Type 2 is by far the most common, accounting for about 90% of cases worldwide. Studies on the role of protein tyrosine phosphatase 1B (PTP1B) have clearly shown that it serves as a key negative regulator of insulin signaling and is involved in the insulin resistance associated with Type 2 diabetes. In the present study, a QSAR modeling work was carried out on a series of 1, 2-naphthoquinone derivatives. The inhibitory activity of such compounds was investigated by two types of QSAR methods: multiple linear regression and non-linear neural networks. This strategy afforded QSAR models with good overall accuracy and predictivity on external data, showing it to be a simple, precise and credible tool to predict and screen 1,2-naphoquinone derivatives with high inhibitory activity.
Export Options
About this article
Cite this article as:
Luan Feng, Xu Xuan, Liu Huitao, Natalia Dias Soeiro Cordeiro Maria and Zhang Xiaoyun, QSAR Studies of PTP1B Inhibitors: 1, 2-Naphthoquinone Derivatives, Letters in Drug Design & Discovery 2012; 9 (10) . https://dx.doi.org/10.2174/1570180811209050915
DOI https://dx.doi.org/10.2174/1570180811209050915 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanocrystals, a New Tool to Study Lipoprotein Metabolism and Atherosclerosis
Current Pharmaceutical Biotechnology PACAP in the Glucose and Energy Homeostasis: Physiological Role and Therapeutic Potential
Current Pharmaceutical Design The Anti-fibrotic Hormone Relaxin is not Reno-protective, Despite Being Active, in an Experimental Model of Type 1 Diabetes
Protein & Peptide Letters Protective Effect of Perindopril on Tumor Progression and Angiogenesis in Animal Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology Anti-Amyloid Treatments in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Novel Natural Agents from Lamiaceae Family: An Evaluation on Toxicity and Enzyme Inhibitory Potential Linked to Diabetes Mellitus
Current Bioactive Compounds High Performance Liquid Chromatographic Approaches to Mass Spectrometry Based Metabolomics
Current Metabolomics Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry
Medicinal Chemistry Renal COX-2, Cytokines and 20-HETE: Tubular and Vascular Mechanisms
Current Pharmaceutical Design Putative Involvement of Endocrine Disruptors in the Alzheimer's Disease Via the Insulin-Regulated Aminopeptidase/GLUT4 Pathway
Current Neuropharmacology Adiponectin - A Novel Anti-Atherogenic Factor in the Metabolic Syndrome: Mechanisms of Action and Therapeutic Potential
Vascular Disease Prevention (Discontinued) Therapeutic Potentials and Cytochrome P450-Mediated Interactions Involving Herbal Products Indicated for Diabetes Mellitus
Drug Metabolism Letters Clinical Determination of the Severity of Metabolic Syndrome: Preheparin Lipoprotein Lipase Mass as a New Marker of Metabolic Syndrome
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design Molecular Hydrogen: New Antioxidant and Anti-inflammatory Therapy for Rheumatoid Arthritis and Related Diseases
Current Pharmaceutical Design Stem Cell Therapies
Recent Patents on Regenerative Medicine Premature Ovarian Insufficiency and Long-Term Health Consequences
Current Vascular Pharmacology Serum Endocan, Neuron-Specific Enolase and Ischemia-Modified Albumin Levels in Newborns with Partial Blood Exchange Transfusion
Combinatorial Chemistry & High Throughput Screening